The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Multiple Myeloma
Abstract
Multiple myeloma, a plasma-cell neoplasm characterized by skeletal destruction, renal failure, anemia, and hypercalcemia, remains incurable. However, recent advances in its treatment, in particular, the use of thalidomide and such new drugs as bortezomib and CC-5013, are promising. This article discusses current therapy for multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationEfficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Smith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Self-citationZangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A. V., Morris, C., Toor, A., Siegel, E., Fink, L., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 491
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2955 · Cited by 403
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
Primary dexamethasone treatment of multiple myeloma
Alexanian, R., Dimopoulos, M., Delasalle, K., & Barlogie, B. (1992) · Blood · doi:10.1182/blood.v80.4.887.887 · Cited by 366
Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., De Laurenzi, A., Facon, T., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02726.x · Cited by 340
VAD‐based regimens as primary treatment for multiple myeloma
Alexanian, R., Barlogie, B., & Tucker, S. (1990) · American Journal of Hematology · doi:10.1002/ajh.2830330203 · Cited by 307
Clinical pharmacology of thalidomide
Eriksson, T., Björkman, S., & Höglund, P. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100320 · Cited by 299
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 294
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L., & Tricot, G. (2002) · Blood · doi:10.1182/blood-2002-01-0335 · Cited by 262
High-Dose Glucocorticoid Treatment of Resistant Myeloma
ALEXANIAN, R., BARLOGIE, B., & DIXON, D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-8 · Cited by 248
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D., Mills, G. M., Barlogie, B., & Salmon, S. E. (2002) · Blood · doi:10.1182/blood.v99.9.3163 · Cited by 240
Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
Osman, K., Comenzo, R., & Rajkumar, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442516 · Cited by 228
Self-citationThalidomide as initial therapy for early-stage myeloma
Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Geyer, S. M., Iturria, N., Kumar, S., Lust, J. A., Kyle, R. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402866 · Cited by 225
Self-citationS.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide
Zeldis, J. B., Williams, B. A., Thomas, S. D., & Elsayed, M. E. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88289-2 · Cited by 223
Hjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rödjer, S., & Westin, J. (1993) · European Journal of Haematology · doi:10.1111/j.1600-0609.1993.tb00148.x · Cited by 220
The Myeloma Trialists' Collaborative Group (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02857.x · Cited by 217
Novel therapies targeting the myeloma cell and its bone marrow microenvironment
HIDESHIMA, T. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90033-8 · Cited by 201
Stewart, A. K., Vescio, R., Schiller, G., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3771 · Cited by 199
Thalidomide in the Treatment of Relapsed Multiple Myeloma
Rajkumar, S. V., Fonseca, R., Dispenzieri, A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Kyle, R. A., Gertz, M. A., & Greipp, P. R. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.9.897 · Cited by 183
Self-citationThalidomide and dexamethasone for resistant multiple myeloma
Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K., & Alexanian, R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04345.x · Cited by 177
Thalidomide for previously untreated indolent or smoldering multiple myeloma
Rajkumar, S., Dispenzieri, A., Fonseca, R., Lacy, M., Geyer, S., Lust, J., Kyle, R., Greipp, P., Gertz, M., & Witzig, T. (2001) · Leukemia · doi:10.1038/sj.leu.2402183 · Cited by 164
Self-citationNew insights into the pathophysiology of multiple myeloma
Seidl, S., Kaufmann, H., & Drach, J. W. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01195-1 · Cited by 160
Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdré, L., Palareti, G., Masini, L., Tura, S., et al. (2002) · Blood · doi:10.1182/blood-2002-06-1674 · Cited by 152
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 137
Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Geyer, S. M., Iturria, N. L., Fonseca, R., Hayman, S. R., Lust, J. A., Kyle, R. A., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.34 · Cited by 136
Self-citationRole of the Bone Marrow Microenvironment in Multiple Myeloma
Roodman, G. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.1921 · Cited by 130
Einsele, H., Schäfer, H., Hebart, H. F., Bader, P., Meisner, C., Plaßwilm, L., Liebisch, P., Bamberg, M., Faul, C., & Kanz, L. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04299.x · Cited by 122
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
Rajkumar, S. V., & Greipp, P. R. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70128-3 · Cited by 116
Self-citationManagement of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113
Current Therapy for Multiple Myeloma
Rajkumar, S. V., Gertz, M. A., Kyle, R. A., & Greipp, P. R. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.8.813 · Cited by 107
Self-citationGoldschmidt, H., Hegenbart, U., Wallmeier, M., Hohaus, S., & Haas, R. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2783095.x · Cited by 107
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
Bladé, J., Perales, M., Rosiñol, L., Tuset, M., Montoto, S., Esteve, J., Cobo, F., Villela, L., Rafel, M., Nomdedeu, B., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02765.x · Cited by 101
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Mehta, J., & Singhal, S. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701459 · Cited by 87
Clinical update: proteasome inhibitors in hematologic malignancies
Richardson, P. G. G. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00080-x · Cited by 80
A prognostic index for multiple myeloma
Grignani, G., Gobbi, P., Formisano, R., Pieresca, C., Ucci, G., Brugnatelli, S., Riccardi, A., & Ascari, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.212 · Cited by 73
Palumbo, J. S., Talmage, K. E., Liu, H., Jeunesse, C. M. L., Witte, D. P., & Degen, J. L. (2003) · Blood · doi:10.1182/blood-2003-03-0881 · Cited by 69
Thalidomide (N‐phthaloylglutamimide> in the treatment of advanced cancer
Olson, K. B., Hall, T. C., Horton, J., & Khung, C. L. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563292 · Cited by 68
García‐Sánz, R., González-Fraile, M. I., Sierra, M., López, C., González, M., & Miguel, J. F. S. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200150 · Cited by 67
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Munshi, N. C. (2001) · The Oncologist · doi:10.1634/theoncologist.6-suppl_2-17 · Cited by 66
Autologous stem cell transplantation for relapsed and primary refractory myeloma
Rajkumar, S. V., Fonseca, R., Lacy, M., Witzig, T., Lust, J., Greipp, P., Therneau, T., Kyle, R. A., Litzow, M., & Gertz, M. A. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701805 · Cited by 66
Self-citationClinical experiences with thalidomide in patients with cancer
Grabstald, H., & Golbey, R. B. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563298 · Cited by 59
Srkalović, G., Elson, P. J., Trebisky, B., Karam, M. A., & Hussein, M. A. (2002) · Medical Oncology · doi:10.1385/mo:19:4:219 · Cited by 48
A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies
Rajkumar, S. V., Mesa, R. A., & Tefferi, A. (2002) · Stem Cells and Development · doi:10.1089/152581602753448522 · Cited by 40
Self-citationEarly harvest and late transplantation as an effective therapeutic strategy in multiple myeloma
Gertz, M. A., Lacy, M., Inwards, D., Chen, M., Pineda, A., Gastineau, D., Greipp, P., Lust, J., Tefferi, A., Witzig, T., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701559 · Cited by 38
Self-citationTreatment Approaches for Relapsing and Refractory Multiple Myeloma
Esteve, J. (2000) · Acta Oncologica · doi:10.1080/028418600750063604 · Cited by 36
Multiple Myeloma: How Far Have We Come?
Anderson, K. C. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.15 · Cited by 35
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
Ghobrial, I. M., Dispenzieri, A. A., Bundy, K. L., Gastineau, D. A., Rajkumar, S. V., Therneau, T. M., Lacy, M. Q., Witzig, T. E., Litzow, M. R., Christensen, B. R., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704173 · Cited by 35
Self-citationShaughnessy, J. D. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.9.1098 · Cited by 18
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Self-citationLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citation
Metadata
- Authors
- Kyle, R. A., & Rajkumar, S. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-28
- Volume
- 351
- Issue
- 18
- Pages
- 1860-1873
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2609515889
- Cited by
- 1,296
- References
- 86
- FWCI
- 45.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.